Table 2. Main results for meta-analysis between SOX2 and clinicopathological Parameters.

clinical parameters	No. of studies	overall OR (95%CI)	Heterogeneity test (Q, I2, P)
Sex (male vs. female)	(1),(4),(5),(6),(7)	1.49 (0.69–3.23)	10.6, 62.3%, 0.312 (random-effect)
Age (>60 vs. < = 60)	(1),(5),(6),(7)	1.30 (0.84–2.01)	3.88, 22.7%, 0.236 (fixed-effect)
Smoking status (yes vs. no)	(1),(4),(5),(7)	2.40 (0.95–6.05)	6.79, 55.8%, 0.065 (random-effect)
Histology (SCCvs. ADC)	(2),(3),(4),(5),(6),(7)	5.26 (1.08–25.6)	78.2, 93.6%, 0.040 (random-effect)
Differentiation (poor vs. well)	(5),(6),(7)	1.97 (0.96–4.05)	0.49, 0.0%, 0.066 (fixed-effect)
Lyphmnodemetastsis (N1 vs. N0)	(4),(5),(7)	1.30 (0.85–1.97)	1.48, 0.0%, 0.226 (fixed-effect)
Stage (III/IV vs. I/II)	(4),(6),(7)	0.89 (0.55–1.44)	2.08, 3.9%, 0.621 (fixed-effect)

Abbreviations: SCC, squamous cell carcinomas; ADC, adenocarcinomas; OR, odds ratios.